{
    "clinical_study": {
        "@rank": "82244", 
        "arm_group": [
            {
                "arm_group_label": "Active", 
                "arm_group_type": "Active Comparator", 
                "description": "NT0102"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a randomized, double-blind, placebo-controlled, parallel group, Phase 3 trial to\n      evaluate the safety and efficacy of NT0102 in the treatment of Attention Deficit\n      Hyperactivity Disorder (ADHD) in pediatric patients 6 to 12 years of age."
        }, 
        "brief_title": "NT0102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Attention Deficit Hyperactivity Disorder (ADHD)", 
        "condition_browse": {
            "mesh_term": [
                "Attention Deficit Disorder with Hyperactivity", 
                "Hyperkinesis"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a randomized, double-blind, placebo-controlled, parallel group, Phase 3 trial to\n      evaluate the safety and efficacy of NT0102 in the treatment of Attention Deficit\n      Hyperactivity Disorder (ADHD) in pediatric patients 6 to 12 years of age in a laboratory\n      classroom study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Currently being treated for ADHD\n\n        Exclusion Criteria:\n\n          -  Other psychiatric diagnoses\n\n          -  Significant cognitive impairment\n\n          -  Chronic medical illnesses\n\n          -  Structural cardiac defects\n\n          -  Significant abnormal lab tests\n\n          -  Taking disallowed medications\n\n          -  Positive drug test"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "12 Years", 
            "minimum_age": "6 Years"
        }, 
        "enrollment": {
            "#text": "84", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01835548", 
            "org_study_id": "NT0102.1004"
        }, 
        "intervention": [
            {
                "arm_group_label": "Active", 
                "description": "One or two tablets once daily", 
                "intervention_name": "NT0102", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "One or two tablets once daily", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "March 26, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Bradenton", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "34208"
                    }, 
                    "name": "Florida Clinical Research Center"
                }, 
                "status": "Completed"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Maitland", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32751"
                    }, 
                    "name": "Florida Clinical Research Center"
                }, 
                "status": "Completed"
            }, 
            {
                "contact": {
                    "email": "dran87@aol.com", 
                    "last_name": "Ann Childress, MD", 
                    "phone": "702-838-0742"
                }, 
                "contact_backup": {
                    "email": "DavidMenard28@gmail.com", 
                    "last_name": "David Menard, BS", 
                    "phone": "(702)838-0742"
                }, 
                "facility": {
                    "address": {
                        "city": "Las Vegas", 
                        "country": "United States", 
                        "state": "Nevada", 
                        "zip": "89128"
                    }, 
                    "name": "Center for Psychiatry and Behavioral Medicine"
                }, 
                "investigator": {
                    "last_name": "Ann Childress, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Durham", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27705"
                    }, 
                    "name": "Duke University"
                }, 
                "status": "Completed"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Multicenter, Double-Blind, Placebo Controlled, Parallel Group Study of NT0102 in Children (Ages 6 12 Years) With Attention-Deficit Hyperactivity Disorder", 
        "other_outcome": {
            "measure": "Incidence of Adverse Events (number and percent of subjects reporting the AE at least once).", 
            "safety_issue": "No", 
            "time_frame": "Screening to Day 75"
        }, 
        "overall_contact": {
            "email": "csikes@neostx.com", 
            "last_name": "Carolyn Sikes, PhD", 
            "phone": "972-408-1300", 
            "phone_ext": "1255"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "SKAMP", 
            "safety_issue": "No", 
            "time_frame": "Week 7"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01835548"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "PERMP", 
            "safety_issue": "No", 
            "time_frame": "Week 7"
        }, 
        "source": "Neos Therapeutics, Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Neos Therapeutics, Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}